- Home
- RRX vs BIO Comparison
RRX vs BIO Comparison
Compare RRX & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RRX
- BIO
- Stock Information
- Founded
- RRX 1955
- BIO 1952
- Country
- RRX United States
- BIO United States
- Employees
- RRX N/A
- BIO N/A
- Industry
- RRX
- BIO Biotechnology: Laboratory Analytical Instruments
- Sector
- RRX
- BIO Industrials
- Exchange
- RRX Nasdaq
- BIO Nasdaq
- Market Cap
- RRX N/A
- BIO 9.2B
- IPO Year
- RRX 1987
- BIO N/A
- Fundamental
- Price
- RRX $118.00
- BIO $243.64
- Analyst Decision
- RRX Strong Buy
- BIO Strong Buy
- Analyst Count
- RRX 9
- BIO 4
- Target Price
- RRX $195.13
- BIO $415.25
- AVG Volume (30 Days)
- RRX 623.5K
- BIO 396.8K
- Earning Date
- RRX 05-05-2025
- BIO 05-06-2025
- Dividend Yield
- RRX 1.19%
- BIO N/A
- EPS Growth
- RRX N/A
- BIO N/A
- EPS
- RRX 2.94
- BIO N/A
- Revenue
- RRX $6,033,800,000.00
- BIO $2,566,500,000.00
- Revenue This Year
- RRX N/A
- BIO $1.11
- Revenue Next Year
- RRX $3.61
- BIO $4.55
- P/E Ratio
- RRX $41.09
- BIO N/A
- Revenue Growth
- RRX N/A
- BIO N/A
- 52 Week Low
- RRX $113.73
- BIO $241.87
- 52 Week High
- RRX $185.28
- BIO $387.99
- Technical
- Relative Strength Index (RSI)
- RRX 36.53
- BIO 32.66
- Support Level
- RRX $117.77
- BIO $243.76
- Resistance Level
- RRX $127.15
- BIO $249.37
- Average True Range (ATR)
- RRX 3.99
- BIO 7.41
- MACD
- RRX 1.09
- BIO 1.77
- Stochastic Oscillator
- RRX 31.80
- BIO 5.34
About BIO Bio-Rad Laboratories Inc.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (56% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (44% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (42% of 2023 sales), Europe (31%), Asia (31%), and other (6%). Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.